Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a...

Full description

Bibliographic Details
Main Authors: Ralph E. White, Maxwell Bannister, Abderrahman Day, Hannah E. Bergom, Victor M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. Drake
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
enzalutamide
SRC kinase inhibitor
Synergy
androgen receptor
phosphorylation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1210487/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1210487/full

Similar Items